Zimmer Biomet Set to Report Q4 Earnings: What's in Store?

Core Viewpoint - Zimmer Biomet Holdings, Inc. is expected to report strong growth in its fourth-quarter 2024 results, driven by performance across its business segments, with revenue and earnings estimates showing positive year-over-year changes [4][3]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues is $2.01 billion, indicating a 3.7% increase from the previous year [3]. - The Zacks Consensus Estimate for earnings is $2.30 per share, reflecting a 4.6% improvement from the year-ago figure [3]. - The earnings estimates have remained steady over the past 90 days [3]. Business Segment Performance - The Hips business is anticipated to show growth due to the company's comprehensive solutions, including the new Z1 triple-taper hip system and the automated HAMMR surgical impactor [5]. - The total Knee business is expected to report a 3.5% year-over-year growth, benefiting from the traction of the cementless Persona OsseoTi and recent FDA approvals [6][8]. - The S.E.T business is projected to achieve a 7.3% year-over-year growth, supported by the FDA approval of the OsseoFit Stemless Shoulder System [9]. Market Position and Challenges - Zimmer Biomet has faced supply challenges in the Knee segment, which are expected to be resolved in the latter half of 2024 [7]. - The company has completed the acquisition of OrthoGrid, enhancing its product portfolio in the hips category [5]. Earnings ESP and Zacks Rank - Zimmer Biomet has an Earnings ESP of 0.00% and currently holds a Zacks Rank of 4 (Sell), indicating a lower chance of beating earnings estimates [11].